

#1910,
Dici
1/29/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Costa et al.

Application No.: 09/332,522

Filed: June 14, 1999

For: Animal Models and Methods
for Analysis of Lipid Metabolism
and Screening of Pharmaceutical
and Pesticidal Agents that
Modulate Lipid Metabolism

Group Art Unit: 1632

Examiner: Shukla, R.

Atty. Docket No.: EX99-004

TECH CENTER 1600/2900

JAN 24 2002

RECEIVED

AMENDMENT AND REPLY AFTER FINAL ACTION
(CFR §§ 1.116 & 1.113)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is responsive to the final office action mailed July 3, 2001. The Commissioner is authorized to charge the requisite fee for a three-month extension of time, and any additional required fees, to deposit account no. 50-1108. A Notice of Appeal is filed herewith

AMENDMENT

Amendment to the claims

Please rewrite claims 1, 13, 22, 23 and 34-36 as follows:

1. (Twice Amended) A *C. elegans* that has been genetically engineered to mis-express an SREBP pathway protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2 (SREBP), SEQ ID NO:94 (SCAP), and SEQ ID NO:95 (S2P), or the progeny of said *C. elegans* that has inherited said mis-expression, wherein said mis-expression results in a loss-of-function intestinal defect phenotype.

Dr. Toenke RPS 4/9/03

Do not enter
RPS
Hayden